These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33300430)

  • 1. Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer.
    Hu Y; Zhang J; Hu H; Xu S; Xu L; Chen E
    Cell Cycle; 2020 Dec; 19(24):3581-3594. PubMed ID: 33300430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of MnO
    Zhang J; Xu L; Hu H; Chen E
    Drug Deliv; 2022 Dec; 29(1):466-477. PubMed ID: 35147070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering EHD1-Targeted Natural Borneol Nanoemulsion Potentiates Therapeutic Efficacy of Gefitinib against Nonsmall Lung Cancer.
    Yuan R; Huang Y; Chan L; He D; Chen T
    ACS Appl Mater Interfaces; 2020 Oct; 12(41):45714-45727. PubMed ID: 32927941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C; Gao W; Liu J; Cheng H; Hao J
    Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
    Zhang K; Wang L; Wei A; Jia X; Liu X
    Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non-small cell lung cancer cells via endoplasmic reticulum stress-mediated degradation of Mcl-1.
    Zhang Q; Chen M; Cao L; Ren Y; Guo X; Wu X; Xu K
    Mol Carcinog; 2020 Jun; 59(6):590-603. PubMed ID: 32189414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling.
    Chen S; Ren Y; Duan P
    Biomed Pharmacother; 2020 Sep; 129():110371. PubMed ID: 32563984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anticancer effects of ginsenoside CK and gefitinib against gefitinib-resistant NSCLC by regulating the balance of angiogenic factors through HIF-1α/VEGF.
    Song X; Wang L; Cai P; Xu Y; Liu Q; Fan D
    Toxicol Appl Pharmacol; 2024 May; 486():116938. PubMed ID: 38642809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
    Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
    Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy.
    Guo H; Wang H; Gao M; Deng H; Zhang Y; Gong J; Zhang W
    Carbohydr Polym; 2024 Nov; 344():122521. PubMed ID: 39218565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway.
    Xie YJ; Gao WN; Wu QB; Yao XJ; Jiang ZB; Wang YW; Wang WJ; Li W; Hussain S; Liu L; Leung EL; Fan XX
    Pharmacol Res; 2020 Sep; 159():104934. PubMed ID: 32464330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and antitumor evaluation of self-assembling oleanolic acid-loaded Pluronic P105/d-α-tocopheryl polyethylene glycol succinate mixed micelles for non-small-cell lung cancer treatment.
    Wu H; Zhong Q; Zhong R; Huang H; Xia Z; Ke Z; Zhang Z; Song J; Jia X
    Int J Nanomedicine; 2016; 11():6337-6352. PubMed ID: 27932881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation
    Wang Y; Guo M; Lin D; Liang D; Zhao L; Zhao R; Wang Y
    Drug Deliv; 2021 Dec; 28(1):1510-1523. PubMed ID: 34263685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.